TABLE 2

Patient Characteristics

Patient no.	Age (y)	¹¹C-acetate injected activity (MBq)	cTNM	TRUS volume (cm³)	Gleason score	PSA (ng/mL)	PSA velocity (ng/mL/y)	Clinical risk group
1	61	704	T2cN0	38	4 + 3	5.8	<0.4	High
2	67	599	T1cN0	103	3 + 2	3.9	<0.4	Low
3	52	487	T1cN0	26	3 + 3	3.0	>1.0	Low
4	46	604	T2cN0	17	3 + 4	30.0	>1.0	High
5	67	625	T2aN0	16	2 + 2	2.9	<0.4	Low
6	55	668	T2aN0	45	3 + 3	11.0	>1.0	Intermediate
7	61	704	T2aN0	22	3 + 3	21.0	>1.0	High
8	55	703	T2aN0	32	3 + 4	16.0	>1.0	Intermediate
9	60	736	T1cN0	32	3 + 3	6.0	>1.0	Low
10	78	556	T1cN0	43	3 + 2	9.9	0.4–1.0	Intermediate
11	69	595	T2cN0	19	3 + 3	6.8	<0.4	Low
12	58	663	T1cN0	54	3 + 4	10.0	<0.4	Intermediate
13	63	586	T2aN0	40	2 + 3	8.4	0.4–1.0	Low
14	63	734	T1cN0	30	3 + 3	20.0	>1.0	Intermediate
15	77	599	T1cN0	36	3 + 3	9.8	<0.4	Low
16	64	727	T2aN0	52	2 + 3	10.0	0.4–1.0	Intermediate
17	66	699	T2cN0	21	5 + 4	8.3	>1.0	High
18	77	452	T2aN0	115	2 + 4	7.0	0.4–1.0	Low
19	63	681	T2aN0	50	3 + 2	14.0	<0.4	Intermediate
20	66	691	T2aN0	40	3 + 4	5.9	0.4–1.0	Intermediate
21	73	687	T2cN0	29	4 + 4	3.1	>1.0	High
Mean	63.9	643		41		10.1
SD	8.27	79		25		6.8